1. Executive Summary
1.1 Research Objectives
1.2 Research Methodology
1.3 Key Findings

2. Non-Alcoholic Steatohepatitis (NASH): an Introduction
2.1 NASH Is A Progressive Form Of Non-alcoholic Fatty Liver Disease
2.2 Currently There Are No Treatments Available For NASH
2.3 NASH Has No Successfully Approved Drug On The Market

3. NASH: Novel Drug Development Process
3.1 New Biomarker Discoveries Have Led To Development Of Multiple INDs
3.2 Factors Affecting Clinical Trial Success Of NASH Candidates
3.3 A High Number Of Clinical Candidates Target Farnesoid X Receptor

4. Clinical Development Landscape of INDs for Treatment of NASH
4.1 A Steady Stream of INDs have Entered Phase 1 Trial Over Last 5 Years
4.2 Pfizer Maintains a Strong Portfolio of Inds for NASH Treatment
4.3 Currently, the Highest Number of Inds are at Phase 2 Studies
4.4 Highest Number of Inds for NASH have Failed at Phase 2 Clinical Trials
4.5 MGL-3196 Is One of the most Promising Candidates for NASH
4.6 Phase 2 Studies also see the most Number of Study Terminations
4.7 Three Inds are Expected to Seek Fda-approval By 2020
4.8 Almost all INDs in Phase 3 are on Fast-track or Breakthrough Designation

5. Comparative Study Of Selected Clinical Candidates
5.1 Comparison of 4 Promising Clinical Candidates for NASH

6. Patent Landscape Assessment
6.1 Patent Research Scope And Concepts
6.2 Top 10 Patent Holding Companies in NASH
6.3 Top 10 Patent Holding Educational Institutes in NASH
6.4 Office-wise Distribution of Patent Portfolio, 2008-2018*
6.5 Year-wise Distribution of NASH Patent Publication Portfolio, 2008-2018*
6.6 Organism-wise Distribution of NASH Patent Publication Portfolio, 2008-2018*

7. Research Innovation Profiles
7.1 Academic Collaborations Bear Fruit for Pharma Companies
7.2 Innovative Drugs in the NASH Pipeline
7.3 Better Disease Models To Improve Human Translation Of Drugs

8. Growth Opportunities
8.1 Growth Opportunity 1: Drug Approval for Treatment of NASH
8.2 Growth Opportunity 2: Better Preclinical Models for NASH
8.3 Growth Opportunity 3: Use of Biomarkers in Clinical Trials

9. Appendix
9.1 Key Contacts